{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T16:02:49Z","timestamp":1765382569212,"version":"3.37.3"},"reference-count":21,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009610","name":"Pontificia Universidad Cat\u00f3lica de Chile","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009610","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["trasci.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.transci.2024.103983","type":"journal-article","created":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T00:31:57Z","timestamp":1722645117000},"page":"103983","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Analysis of apheresis outcomes in a cohort of Chilean patients treated with autologous stem cell transplantation: A single center real-world experience"],"prefix":"10.1016","volume":"63","author":[{"given":"M","family":"Sarmiento","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Salinas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Jara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MJ","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MJ","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Flores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Sandoval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Vergara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Palacios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Ocqueteau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.transci.2024.103983_bib1","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/bmt.2014.39","article-title":"Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European group for blood and marrow transplantation","volume":"49","author":"Mohty","year":"2014","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.transci.2024.103983_bib2","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1182\/blood.V89.7.2233","article-title":"et\u202fal. The biology and clinical uses of blood stem cells","volume":"89","author":"ToL","year":"1997","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.transci.2024.103983_bib3","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jtct.2020.12.009","article-title":"Low-Dose Cyclophosphamide versus intermediate-high-dose cyclophosphamide versus granulocyte colony-stimulating factor alone for stem cell mobilization in multiple myeloma in the era of novel agents: a multicenter retrospective study","volume":"27","author":"Zannetti","year":"2021","journal-title":"Transpl Cell Ther"},{"issue":"10","key":"10.1016\/j.transci.2024.103983_bib4","article-title":"Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma","author":"Hartmann","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.transci.2024.103983_bib5","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1537-2995.2005.04222.x","article-title":"Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist","volume":"45","author":"Liles","year":"2005","journal-title":"Transfusion"},{"issue":"4","key":"10.1016\/j.transci.2024.103983_bib6","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41409-017-0051-y","article-title":"Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score","volume":"53","author":"Olivieri","year":"2018","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"10.1016\/j.transci.2024.103983_bib7","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/trf.12813","article-title":"Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma","volume":"55","author":"Cheng","year":"2015","journal-title":"Transfusion"},{"issue":"11","key":"10.1016\/j.transci.2024.103983_bib8","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/bmt.2012.60","article-title":"Growth factor plus preemptive ('just-in-time') plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure","volume":"47","author":"Costa","year":"2012","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"10.1016\/j.transci.2024.103983_bib9","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/trf.12265","article-title":"Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma","volume":"54","author":"Lanza","year":"2014","journal-title":"Transfusion"},{"issue":"3","key":"10.1016\/j.transci.2024.103983_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2020.102785","article-title":"New horizons on stem cell cryopreservation through the artificial eyes of CD34+, using modern flow cytometry tools","volume":"59","author":"Lanza","year":"2020","journal-title":"Transfus Apher Sci"},{"issue":"7","key":"10.1016\/j.transci.2024.103983_bib11","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/sj.bmt.1704637","article-title":"High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma","volume":"34","author":"Wang","year":"2004","journal-title":"Bone Marrow Transpl"},{"issue":"8","key":"10.1016\/j.transci.2024.103983_bib12","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/s41409-018-0117-5","article-title":"Advantages of non-cryopreserved autologous hematopoietic stem cell transplantation against a cryopreserved strategy","volume":"53","author":"Sarmiento","year":"2018","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"10.1016\/j.transci.2024.103983_bib13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.htct.2019.01.010","article-title":"Haploidentical transplantation outcomes are comparable with those obtained with identical human leukocyte antigen allogeneic transplantation in Chilean patients with benign and malignant hemopathies","volume":"42","author":"Sarmiento","year":"2020","journal-title":"Hematol Transfus Cell Ther"},{"issue":"8","key":"10.1016\/j.transci.2024.103983_bib14","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/s41409-022-01691-w","article-title":"European society for blood and marrow transplantation (EBMT). Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022","volume":"57","author":"Snowden","year":"2022","journal-title":"Bone Marrow Transpl"},{"issue":"11","key":"10.1016\/j.transci.2024.103983_bib15","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/bmt.2016.174","article-title":"Autologous stem cell transplant for multiple myeloma patients 70 years or older","volume":"51","author":"Muchtar","year":"2016","journal-title":"Bone Marrow Transpl"},{"issue":"6","key":"10.1016\/j.transci.2024.103983_bib16","first-page":"475","article-title":"A German-wide systematic study on mobilization and collection of hematopoietic stem cells in poor mobilizer patients with multiple myeloma prior to autologous stem cell transplantation","volume":"50","author":"Bittrich","year":"2023","journal-title":"Transfus Med Hemother"},{"issue":"9","key":"10.1016\/j.transci.2024.103983_bib17","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/ajh.23499","article-title":"Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization","volume":"88","author":"Smith","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.transci.2024.103983_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101811","article-title":"An evidence-based and risk-adapted GSF versus GSF plus plerixafor mobilization strategy to obtain a sufficient CD34+ cell yield in the harvest for autologous stem cell transplants","volume":"39","author":"Balint","year":"2024","journal-title":"Transl Oncol"},{"issue":"1","key":"10.1016\/j.transci.2024.103983_bib19","doi-asserted-by":"crossref","first-page":"2329140","DOI":"10.1080\/07853890.2024.2329140","article-title":"G-CSF\u202f+\u202fplerixafor versus G-CSF alone mobilized hematopoietic stem cells in patients with multiple myeloma and lymphoma: a systematic review and meta-analysis","volume":"56","author":"Li","year":"2024","journal-title":"Ann Med"},{"issue":"6","key":"10.1016\/j.transci.2024.103983_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2023.103830","article-title":"Overview on novel strategies and current guidelines for hematopoietic stem cell mobilisation and collection","volume":"62","author":"Lanza","year":"2023","journal-title":"Transfus Apher Sci"},{"issue":"3","key":"10.1016\/j.transci.2024.103983_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2024.103931","article-title":"Novel approaches for hematopoietic stem cell mobilisation and collection need to be assessed for qualification and validation to accomplish the proper requirements of their intended purpose","volume":"63","author":"Lanza","year":"2024","journal-title":"Transfus Apher Sci"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147305022400154X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147305022400154X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T20:42:09Z","timestamp":1732567329000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S147305022400154X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S147305022400154X"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2024.103983","relation":{},"ISSN":["1473-0502"],"issn-type":[{"type":"print","value":"1473-0502"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of apheresis outcomes in a cohort of Chilean patients treated with autologous stem cell transplantation: A single center real-world experience","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2024.103983","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103983"}}